Home

C2N Diagnostics and WashU Medicine Teams Receive Prestigious Award from Human Proteome Organization

via Business Wire

The Human Proteome Organization (HUPO), the nonprofit international scientific organization that represents and promotes proteomics on a global stage, has named team members of C2N Diagnostics, LLC (“C2N”) and Washington University School of Medicine in St. Louis (WashU Medicine) laboratories of Dr. Randall Bateman and Dr. David Holtzman as its 2025 Science and Technology Award recipients. Dr. Joel Braunstein, CEO and President of C2N, accepted the award on behalf of the recipients at the 24th Human Proteome Organization World Congress meeting, which is occurring Nov. 9-13 in Toronto, Canada.

HUPO says it selected the C2N and WashU Medicine teams because their “exceptional achievements have significantly advanced the field of proteomics. Each award recognizes excellence, innovation, and impactful contributions to the global scientific community.”

Starting as a technology spin-out from the Bateman and Holtzman labs at WashU Medicine, C2N has established itself as a leading innovator in the field of high-performance blood biomarkers to aid in the early diagnosis of Alzheimer’s disease. It accomplishes this through ongoing close collaboration with the Bateman and Holtzman labs, a talented team of its own scientists, and using a proprietary set of methods, reagents, and mass spectrometry-based proteoform identification (isoforms and post-translation modifications) for the creation of multi-analyte assays with algorithmic analyses that it applies to clinical drug development and Alzheimer’s disease diagnosis.

Dr. Braunstein says, “I join my colleagues in thanking the Human Proteome Organization for this important recognition of our hard work and dedication, along with our collaborators at WashU Medicine. We fully embrace HUPO’s mission of fostering the development of new proteomics technologies, techniques, and training, and that’s what makes this award all the more meaningful. The award is also a testament to team members’ abilities to collaborate in taking an innovation from labs to healthcare professionals and their patients.”

Precivity™ Tests: Breakthrough Innovation Tied to Proteomics

In 2020, C2N introduced the first analytically and clinically validated blood biomarker, the PrecivityAD® test, for use in clinical care within the United States. During mid-2023, C2N introduced into clinical care the first p-tau217 (%p-tau217, p-tau217/np-tau217) assay as part of a second-generation test, PrecivityAD2™, that combined Aβ42/40 and %p-tau217 into a validated algorithm, achieving a superb level of clinical diagnostic performance to measure amyloid comparable to the current gold standards of amyloid PET and CSF biomarkers. Both tests were developed in collaboration with Bateman and Holtzman.

In 2024, the company introduced to the commercial research market a proprietary, analytically and clinically validated mass spec method to measure Tau-MTBR based upon pioneering work in the Bateman and Holtzman labs, demonstrating that it is now possible to stage not only amyloid pathology but also tau pathology with the addition of Tau-MTBR.

As a testament to the over 15-year journey to build a best-in-class clinical solution for a major global unmet medical need in Alzheimer’s disease (AD), a landmark paper published in 2024 in the Journal of the American Medical Association showed that the PrecivityAD2 test result markedly improved the accuracy of AD diagnosis among patients with cognitive concerns presenting in primary care settings or who saw memory care specialists.

Last month, the company submitted to the U.S. Food & Drug Administration a regulatory filing for its Alzheimer’s disease blood test. C2N states that it seeks to establish a first in the field of medicine with its pioneering diagnostic algorithm test using high resolution mass spectrometry, which empowers health care professionals to detect brain amyloid pathology — one of the defining hallmarks of Alzheimer’s disease — with greater ease and confidence.

About C2N Diagnostics, LLC

C2N is a specialty diagnostics company with a vision to bring Clarity Through Innovation®. C2N strives to provide exceptional clinical laboratory services and advanced diagnostic solutions in the field of brain health. C2N’s high-resolution mass spectrometry-based biomarker services and products are used for: clinical decision-making to improve patient care, including diagnosis and treatment monitoring; maximizing the quality and efficiency of clinical trials that test novel treatments for neurodegeneration; and providing innovative tools to help healthcare researchers better understand novel mechanisms of disease, identify new treatment targets, and conduct important epidemiologic studies to improve global public health. C2N assays have been used in over 150 Alzheimer’s disease and other research studies throughout the U.S. and the world. This includes landmark treatment and prevention trials involving disease-modifying therapies (DMTs) that are changing the trajectory of Alzheimer’s disease. C2N has ongoing collaborations with multi-national pharmaceutical and biotech companies, leading academic institutions, National Institute on Aging, Alzheimer’s Association, and other non-profits and consortiums in addition to research and distribution partnerships with leading labs around the world including Grupo Fleury, Healius, Mediford, and Mayo Clinic Laboratories Over 50,000 Precivity™-related biomarker measures have been reported through peer-reviewed publications, with many more manuscripts currently under review.

The company acknowledges generous support from National Institute on Aging, GHR Foundation, Alzheimer’s Drug Discovery Foundation, BrightFocus Foundation, Alzheimer’s Association and The Michael J. Fox Foundation. For more information visit www.c2n.com.

C2N President and CEO Dr. Joel Braunstein says, “I join my colleagues in thanking the Human Proteome Organization for this important recognition of our hard work and dedication, along with our collaborators at WashU Medicine."

Contacts